Cargando…
The effect of different chemotherapeutic agents on the enrichment of DNA mismatch repair-deficient tumour cells.
Loss of DNA mismatch repair is a common finding in hereditary non-polyposis colon cancer as well as in many types of sporadic human tumours. We compared the effect of loss of DNA mismatch repair on drug sensitivity as measured by a clonogenic assay with its effect on the ability of the same drug to...
Autores principales: | Fink, D., Nebel, S., Norris, P. S., Aebi, S., Kim, H. K., Haas, M., Howell, S. B. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2149976/ https://www.ncbi.nlm.nih.gov/pubmed/9514047 |
Ejemplares similares
-
Expression of the DNA mismatch repair proteins hMLH1 and hPMS2 in normal human tissues.
por: Fink, D., et al.
Publicado: (1997) -
Photodynamic therapy of DNA mismatch repair-deficient and -proficient tumour cells
por: Schwarz, V A, et al.
Publicado: (2002) -
Induction of JNK and c-Abl signalling by cisplatin and oxaliplatin in mismatch repair-proficient and -deficient cells
por: Nehmé, A, et al.
Publicado: (1999) -
Loss of DNA mismatch repair facilitates reactivation of a reporter plasmid damaged by cisplatin
por: Cenni, B, et al.
Publicado: (1999) -
Brostallicin (PNU-166196) – a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells
por: Fedier, A, et al.
Publicado: (2003)